Most-Downgraded Stocks NASDAQ:GRPH Graphite Bio - GRPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Graphite Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.37 +0.04 (+1.72%) (As of 03/22/2023 03:46 PM ET) Add Compare Share Share Today's Range$2.24▼$2.4450-Day Range$1.91▼$2.6952-Week Range$1.59▼$6.16Volume147,644 shsAverage Volume317,580 shsMarket Capitalization$137.82 millionP/E RatioN/ADividend YieldN/APrice Target$5.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Graphite Bio MarketRank™ ForecastAnalyst RatingHold1.89 Rating ScoreUpside/Downside131.0% Upside$5.43 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.39) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector440th out of 983 stocksBiological Products, Except Diagnostic Industry74th out of 163 stocks 3.9 Analyst's Opinion Consensus RatingGraphite Bio has received a consensus rating of Hold. The company's average rating score is 1.89, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.43, Graphite Bio has a forecasted upside of 131.0% from its current price of $2.35.Amount of Analyst CoverageGraphite Bio has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GRPH. Previous Next 0.0 Dividend Strength Dividend YieldGraphite Bio does not currently pay a dividend.Dividend GrowthGraphite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRPH. Previous Next 2.5 News and Social Media Coverage News SentimentGraphite Bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Graphite Bio this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Graphite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.45% of the stock of Graphite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.51% of the stock of Graphite Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Graphite Bio are expected to grow in the coming year, from ($1.39) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Graphite Bio is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Graphite Bio is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGraphite Bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Graphite Bio (NASDAQ:GRPH) StockGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More Receive GRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRPH Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comGraphite Bio (NASDAQ:GRPH) Issues Earnings ResultsMarch 22, 2023 | americanbankingnews.comGraphite Bio (NASDAQ:GRPH) Posts Earnings Results, Beats Estimates By $0.05 EPSMarch 22, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 21, 2023 | markets.businessinsider.comBTIG Sticks to Its Hold Rating for Graphite Bio (GRPH)March 20, 2023 | finance.yahoo.comGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial ResultsMarch 18, 2023 | americanbankingnews.comContrasting Inhibrx (NASDAQ:INBX) & Graphite Bio (NASDAQ:GRPH)March 18, 2023 | americanbankingnews.comReviewing Inhibrx (NASDAQ:INBX) and Graphite Bio (NASDAQ:GRPH)March 17, 2023 | americanbankingnews.comGraphite Bio, Inc. (NASDAQ:GRPH) Given Average Recommendation of "Hold" by BrokeragesMarch 22, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 24, 2023 | marketwatch.comGraphite Bio to Reduce Workforce by 50%, Explores Strategic AlternativesFebruary 24, 2023 | benzinga.comGraphite Bio shares are trading higher after the company announced a process to explore strategic alternatives.February 23, 2023 | finance.yahoo.comSickle-cell gene therapy developer stops program, cuts half of staffFebruary 23, 2023 | msn.comGraphite Bio adds 10%, most in eight months even as downgrades pile upFebruary 22, 2023 | finance.yahoo.comGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate RestructuringJanuary 25, 2023 | markets.businessinsider.comExpert Ratings for Graphite BioJanuary 10, 2023 | finance.yahoo.comDown -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a TurnaroundJanuary 9, 2023 | msn.comLooking Into Graphite Bio's Recent Short InterestJanuary 5, 2023 | finance.yahoo.comGraphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell DiseaseJanuary 5, 2023 | finance.yahoo.comGraphite Bio pauses early-stage blood disease therapy trialDecember 12, 2022 | barrons.comGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64(th) ASH Annual MeetingDecember 11, 2022 | finance.yahoo.comGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual MeetingDecember 9, 2022 | seekingalpha.comGraphite Bio: Underfollowed Gene Editing Play At An Attractive ValuationNovember 21, 2022 | finance.yahoo.comGraphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx ConferenceNovember 9, 2022 | finance.yahoo.comGraphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial ResultsNovember 5, 2022 | barrons.comGraphite Bio Announces Abstracts Accepted for Upcoming 64(th) ASH Annual Meeting and ExpositionNovember 3, 2022 | finance.yahoo.comGraphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and ExpositionOctober 16, 2022 | finance.yahoo.comHere's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn SituationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRPH Company Calendar Last Earnings3/20/2023Today3/22/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRPH CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.43 High Stock Price Forecast$18.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+139.1%Consensus RatingHold Rating Score (0-4)1.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.25% Return on Assets-25.97% Debt Debt-to-Equity RatioN/A Current Ratio22.07 Quick Ratio22.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.61 per share Price / Book0.35Miscellaneous Outstanding Shares58,150,000Free Float35,793,000Market Cap$135.49 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Joshua Lehrer-Graiwer FACC (Age 48)M.D., Pres, CEO & Director Comp: $724.58kDr. Matthew Porteus M.D. (Age 57)Ph.D., Academic Founder & Director Comp: $90.77kDr. Maria Grazia Roncarolo M.D. (Age 68)Ph.D., Academic Founder & Chair of Scientific Advisory Board Comp: $70kMr. Philip P. Gutry (Age 49)Chief Bus. Officer Comp: $541.33kDr. Daniel Dever Ph.D.Co-Founder & Head of Discovery ResearchMs. Alethia Rene Young (Age 43)Chief Financial Officer Dr. Christine Garrett P.M.P. (Age 51)Ph.D., Chief of Staff & Sr. VP of Operations Mr. Jerry Cacia (Age 55)Chief Technical Officer Dr. Jane Grogan Ph.D. (Age 54)Chief Scientific Officer Stephanie YaoVP of Communications & Investor RelationsMore ExecutivesKey CompetitorsSorrento TherapeuticsNASDAQ:SRNEIkena OncologyNASDAQ:IKNAINmune BioNASDAQ:INMBGenenta ScienceNASDAQ:GNTACidara TherapeuticsNASDAQ:CDTXView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 217,325 shares on 2/15/2023Ownership: 0.229%Man Group plcBought 72,573 shares on 2/15/2023Ownership: 0.192%Boothbay Fund Management LLCBought 28,463 shares on 2/15/2023Ownership: 0.049%Belvedere Trading LLCBought 24,000 shares on 2/15/2023Ownership: 0.000%Annandale Capital LLCBought 17,930 shares on 2/15/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions GRPH Stock - Frequently Asked Questions Should I buy or sell Graphite Bio stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last year. There are currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRPH, but not buy additional shares or sell existing shares. View GRPH analyst ratings or view top-rated stocks. What is Graphite Bio's stock price forecast for 2023? 9 analysts have issued twelve-month price objectives for Graphite Bio's shares. Their GRPH share price forecasts range from $2.00 to $18.00. On average, they predict the company's stock price to reach $5.43 in the next twelve months. This suggests a possible upside of 133.0% from the stock's current price. View analysts price targets for GRPH or view top-rated stocks among Wall Street analysts. How have GRPH shares performed in 2023? Graphite Bio's stock was trading at $3.32 at the beginning of the year. Since then, GRPH stock has decreased by 29.8% and is now trading at $2.33. View the best growth stocks for 2023 here. When is Graphite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our GRPH earnings forecast. How were Graphite Bio's earnings last quarter? Graphite Bio, Inc. (NASDAQ:GRPH) announced its quarterly earnings results on Monday, March, 20th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.05. When did Graphite Bio IPO? (GRPH) raised $224 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. What is Graphite Bio's stock symbol? Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH." Who are Graphite Bio's major shareholders? Graphite Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (9.82%), Privium Fund Management UK Ltd (1.05%), Board of Trustees of The Leland Stanford Junior University (0.79%), Renaissance Technologies LLC (0.57%), Geode Capital Management LLC (0.42%) and GSA Capital Partners LLP (0.37%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry. View institutional ownership trends. How do I buy shares of Graphite Bio? Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Graphite Bio's stock price today? One share of GRPH stock can currently be purchased for approximately $2.33. How much money does Graphite Bio make? Graphite Bio (NASDAQ:GRPH) has a market capitalization of $135.49 million. The company earns $-70,760,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. How can I contact Graphite Bio? The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com. This page (NASDAQ:GRPH) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.